Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
45,417,666
-
Share change
-
+13,508,576
-
Total reported value
-
$1,298,594,000
-
Put/Call ratio
-
64%
-
Price per share
-
$25.20
-
Number of holders
-
95
-
Value change
-
+$509,363,836
-
Number of buys
-
64
-
Number of sells
-
40
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2021
As of 31 Mar 2021,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,417,666 shares.
The largest 10 holders included
VR Adviser, LLC, Rock Springs Capital Management LP, Foresite Capital Management IV, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, Cormorant Asset Management, LP, Foresite Capital Management III, LLC, Parkman Healthcare Partners LLC, and Vivo Capital, LLC.
This page lists
95
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.